Most people with SCD seem to meet or exceed current level of physical activity recommendations for the general population, a ...

To mark four years of sharing his experiences through writing, columnist Dunstan Nicol-Wilson reflects on the journey with gratitude.

Columnist Oluwatosin Adesoye shares her thoughts about the role of World Sickle Cell Day in promoting sickle cell awareness.

BEAM-101, a treatment for sickle cell disease, showed sustained efficacy and safety over one year in the BEACON Phase 1/2 ...

Michela Luciano is a Science Writer at BioNews. Originally from the picturesque mountain town of L’Aquila, Italy, Michela holds a PhD in Molecular Biology from the University of Salzburg, where her ...

The BEACON trial (NCT05456880), which began dosing last year, is evaluating the safety and efficacy of BEAM-101 in people with severe SCD, ages 18-35, who have had at least four VOCs in the two years ...